IVM Versus IVF in High Antral Follicle Count Patients
Launched by MỸ ĐỨC HOSPITAL · Jan 13, 2018
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
Women with PCOS and PCOM or high AFC: ≥24 Antral Follicles in Both Ovaries will be given the information about the study during the first consultation which is at least 2 weeks before having periods. On the second day of periods, women will be screened for eligibility by the treating clinicians. Women who met the inclusion criteria will be invited to participate in the study. Women will be randomized (1:1) to IVM or IVF- GnRH agonist triggering cycle using block randomization by an independent study coordinator via telephone, using a computer-generated random list (block size 2, 4, 6 or 8)....
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women with high AFC (≥24 Antral Follicles in Both Ovaries), including PCOS plus PCO or high AFC
- • Having indications for ART
- • Having ≤ 2 IVM/IVF attempts
- • Permanent resident in Vietnam
- • Agree to have all embryos frozen on day 3
- • Agree to have ≤ 2 embryos transferred in a subsequent frozen transfer
- • Not participating in another IVF study at the same time
- Exclusion Criteria:
- • Oocyte donation cycles
- • Pre-implantation genetic diagnosis (PGD) cycles
About Mỹ đức Hospital
Mỹ Đức Hospital is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. With a strong emphasis on ethical practices and patient safety, the hospital collaborates with reputable research organizations and healthcare professionals to conduct studies across various therapeutic areas. Committed to excellence in clinical research, Mỹ Đức Hospital leverages its state-of-the-art facilities and experienced staff to contribute valuable insights that enhance medical knowledge and treatment options for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ho Chi Minh City, Tan Binh, Vietnam
Patients applied
Trial Officials
Lan N Vuong, MD,PhD
Principal Investigator
Mỹ Đức Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials